Hamlet Pharma AB and Linnane Pharma AB entered into a licensing agreement on 12 May 2020, for the development of BAMLET; a complex formed by bovine alpha-lactalbumin and oleic acid. According to the agreement, Linnane Pharma would under Hamlet Pharma's patents develop the product BAMLET for non-pharmaceutical use. Since then, Linnane Pharma has worked intensively to drive the project forward. However, the board of Linnane Pharma has acknowledged synergies if Hamlet Pharma decides to develop BAMLET as a drug, not least in terms of manufacturing and formulation. The board of Linnane Pharma has therefore proposed that the licensing agreement from 12 May be terminated. The board of Hamlet Pharma has accepted the proposal from Linnane Pharma and thus all rights have been returned to Hamlet Pharma without any compensation to Linnane Pharma.